Skip to main content

Web Exclusives

Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD

Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension

Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis

Weight Loss Intervention Fails to Reduce Cardiovascular Events in Type 2 Diabetes, but Has Positive Effect on Other Measures

Low-Cost Phone Intervention Helps with Weight Loss, Glycemic Control

Symptomatic hypoglycemia increases risk of cardiovascular events, death in type 2 diabetes

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Page 27 of 37
Results 261 - 270 of 362